MindWalk Announces B Cell Llama Platform for Nanobody Discovery in Bispecific and Cell Therapy Era

MindWalk Holdings Corp. announced B Cell Llama™, a platform for the discovery of VHH nanobodies for bispecific and cell therapy applications. The platform aims to help partners capture the opportunity in the $50 billion bispecific antibody market and the broader cell therapy market. B Cell Llama™ extends MindWalk's B Cell Select platform and leverages AI to guide the discovery process, from target selection to multispecific construct evaluation. The platform is designed to overcome molecular engineering challenges in drug development and improve the efficacy of VHH nanobodies.